Brief: Aridis Pharmaceuticals' AR-301 Eligible For Consideration Under FDA’S Limited Population Pathway For Antibacterial And Antifungal Drugs
20/06/2023 15:24
June 20 (Reuters) - Aridis Pharmaceuticals Inc ARDS.O :
* ARIDIS PHARMACEUTICALS' AR-301 ELIGIBLE FOR CONSIDERATION
UNDER
FDA’S LIMITED POPULATION PATHWAY FOR ANTIBACTERIAL AND
ANTIFUNGAL DRUGS (LPAD)
Source text for Eikon: ID:nGNX4Mk8Vd
Further company coverage: ARDS.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Aridis Pharmaceuticals
See all newsBrief: Aridis Pharmaceuticals Inc - On September 7 Nasdaq Announced That It Would Delist Common Stock Of Co
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
U.S. STOCKS ON THE MOVE-Teladoc Health, NVDIA, Chipotle
U.S. STOCKS ON THE MOVE-Pinterest, Sunrun, Tencent Music